Viracta Therapeutics Inc (RYIS.MU)
| Previous Close | 3.58 |
| Open | 3.58 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 3.58 - 12.53 |
| 52 Week Range | 0.41 - 12.53 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireViracta Therapeutics Announces New Employment Inducement Grants
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta’s new Chief Financial Officer, Viracta’s Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta’s 2021 Inducement Eq
- GlobeNewswire
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. “We are delighted to
- GlobeNewswire
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate Nana-val’s “Kick and Kill” mechanism of action; additional data are expected in the third quarter of 2024 Plan to engage with U.S. Food and Drug Administration (FDA) in mid-2024 to align on requirements for accelerated approval
